Thesis:
Gilead Sciences (GILD) has been relatively stagnant since the end of FY15 with the fall of its Hepatitis C ((HCV)) portfolio sales. Gilead's HCV sales for FY15 reached levels near $19 billion; current trailing 12-month HCV sales now sit a bit over $3 billion. However, Gilead has exhibited impressive growth with its Human Immunodeficiency Virus ((HIV)) product sales and is finally reaping the fruits of the pricey Kite Pharma acquisition. Gilead has also significantly strengthened its inflammation and fibrosis portfolio with its deepened collaboration with Galapagos (GLPG). Furthermore, Gilead's